Biogen Expands Isis Partnership in $100 Million Drug Deal

Biogen Idec Inc. (BIIB), the maker of the multiple sclerosis pill Tecfidera, expanded its partnership with Isis Pharmaceuticals Inc. (ISIS) in a deal worth at least $100 million to develop drugs for neurological disorders.

Biogen will pay Carlsbad, California-based Isis $100 million upfront and as much as $220 million per compound in potential milestone payments, the companies said today in a statement. The six-year deal gives Weston, Massachusetts-based Biogen exclusive access to Isis’s antisense technology platform to identify targets and develop drugs for neurological diseases.

Antisense therapy works on the underlying genetic causes of disease, turning genes on or off to fix a defect. The agreement expands on three others Biogen has signed with Isis in the last two years, including one to develop a drug for spinal muscular atrophy.

“This is a more expansive collaboration,” Biogen Chief Executive Officer George Scangos said in a telephone interview. “The teams have worked extraordinarily well together.”

Spinal muscular atrophy is a good example of a disorder on which the companies would collaborate, Stanley Crooke, Isis’s chief executive, said. A rare genetic disorder, the most severe form of SMA is characterized by very little production of a specific protein, and can kill patients before age 2.

Photographer: Scott Eells/Bloomberg

Biogen Chief Executive Officer George Scangos said, “This is a more expansive collaboration.” Close

Biogen Chief Executive Officer George Scangos said, “This is a more expansive collaboration.”

Close
Open
Photographer: Scott Eells/Bloomberg

Biogen Chief Executive Officer George Scangos said, “This is a more expansive collaboration.”

Isis rose 14 percent to $31.81 at 4 p.m. New York time, its biggest one-day increase since June 24. Biogen shares gained 1.6 percent to $228.86.

Lou Gehrig’s Disease

The companies may also target diseases such as amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, Crooke and Scangos said. Biogen had been developing a drug for ALS, dexpramipexole, that failed to show any benefit earlier this year in the last stage of clinical trials.

“Biogen has a pretty aggressive program to understand more about the genetic causes of ALS,” Scangos said. One part of that, an academic group, is “already generating interesting insights into the biology and some potential targets we would hope to be able to take forward.”

The partnership is the first for Isis around an entire therapeutic area, Crooke said. The company doesn’t have a sales force, preferring to make partnerships with larger drugmakers to run late-stage clinical studies and to market its medicines. Its first approved drug, Kynamro, for a rare cholesterol disorder, is marketed by Sanofi (SAN)’s Genzyme unit.

Isis may try to do more deals similar to this one, Crooke said.

“This is the next step in the evolution of our partnering strategy,” Crooke said. “It makes a lot of sense for us; what we need is to make sure our partners understand our technology, are ready for the drugs when they’re ready for them, and that there are people in the organizations we can trust to do a good job with our assets.”

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.